Key Takeaways:
- FDA approved Wegovy HD (semaglutide 7.2 mg) on March 19, marking the first GLP-1 approved under the new National Priority Voucher program
- Clinical trials showed 20.7% mean weight loss, with one in three people achieving 25% or greater weight loss
- Approval came in 54 days versus standard 10-12 month timeline, with US launch expected April 2026
- Higher dose is only for adults who have tolerated 2.4 mg for at least 4 weeks and need additional weight reduction
FDA Fast-Tracks Record-Breaking Weight Loss Drug
The U.S. Food and Drug Administration approved a new higher dose (7.2 mg) of Wegovy (semaglutide) injection, called Wegovy HD, for weight loss and long-term maintenance of weight loss for certain adult patients on March 19, 2026. This approval represents a significant milestone — not for the unprecedented weight loss results, but for how quickly it moved through regulatory review.
The approval marks the first glucagon-like peptide-1 (GLP-1) receptor agonist approved under the Commissioner's National Priority Voucher (CNPV) program, granted 54 days after filing compared with the standard 10- to 12-month review timeline. The expedited review reflects the drug's potential to address what regulators see as critical national health priorities.
"The new FDA is moving with unprecedented efficiency on products that advance national priorities," FDA Commissioner Martin Makary said. "Today's approval is another demonstration of what the FDA can accomplish when we try bold new things."
Clinical Results Show Unprecedented Weight Loss
The approval is based on results from the phase 3b STEP UP trial program, which demonstrated weight loss results that exceed anything previously seen with GLP-1 medications. In the STEP UP trial, semaglutide 7.2 mg injected once weekly demonstrated 20.7% mean weight loss in participants with obesity, and approximately one in three people experienced 25% or greater weight loss.
To put this in perspective, the existing 2.4 mg Wegovy formulation produces approximately 15% mean weight loss in its pivotal trials, positioning the higher dose as a meaningful step forward for people who need greater weight reduction. The 72-week trial included 1,407 adults with obesity (body mass index of 30 or higher) without diabetes, randomly assigned to receive the new high dose, standard dose, or placebo.
Results showed people treated with semaglutide 7.2mg achieved superior weight loss of 20.7% compared with 17.5% in the 2.4mg group and 2.4% for those on placebo. Additionally, 31.2% of people in the high-dose group achieved at least 25% weight loss versus 16.7% in the standard dose group.
For people with both obesity and type 2 diabetes, semaglutide 7.2 mg demonstrated a mean weight loss of 14.1% in the separate STEP UP T2D trial.
Who Can Access Wegovy HD and How
Semaglutide 7.2 mg is indicated for adults with obesity who have tolerated the 2.4-mg dose for at least 4 weeks and for whom additional weight reduction is clinically indicated. This makes it a step-up option rather than a first-line treatment.
Novo Nordisk expects to launch Wegovy HD in a single-dose pen in the US in April 2026, making it available through the same channels as existing formulations. Wegovy HD will be available through all channels where you can access Wegovy including 70,000 plus pharmacies in the US like CVS and Costco, select telehealth providers, NovoCare Pharmacy, GoodRx, and others.
If you're looking for the most convenient way to access GLP-1 medications, our compare telehealth providers tool can help you find platforms that will likely offer Wegovy HD once it launches.
Safety Profile Shows New Side Effect Pattern
While the higher dose delivered superior weight loss, it also came with some distinct safety considerations. The most common adverse reactions observed were gastrointestinal, including nausea, vomiting, diarrhea, constipation, and abdominal pain — similar to other GLP-1 medications.
However, researchers noted a new pattern of side effects. Dysesthesia—altered skin sensation described as sensitivity, pain, or burning—occurred more frequently at the higher dose (22.9%) versus 2.4 mg (6.0%) or placebo (0.5%). These symptoms generally resolved on their own or with dose reduction.
The FDA is currently conducting further investigations regarding this drug reaction, though the agency still determined the benefits outweighed the risks for approval.
More than 70% of people taking the higher Wegovy dose reported issues such as nausea, vomiting or constipation, compared to over 60% with the lower dose and around 43% with a placebo.
How This Changes the GLP-1 Treatment Landscape
Wegovy HD represents the latest evolution in what's becoming an increasingly sophisticated approach to weight management. Semaglutide 7.2 mg joins the existing US Wegovy portfolio, which includes the 25 mg once-daily pill and once-weekly injections at 1.7 mg and 2.4 mg.
For people who do not achieve sufficient weight loss on the 2.4 mg dose, the higher-dose option may offer a meaningful step-up within the same drug class before consideration of surgical intervention.
Dr. Jody Dushay, an endocrinologist at Harvard Medical School, explained that the new option "may be especially helpful for people" who tolerate the lower dose but "have had suboptimal weight loss." She added it could also help people who don't respond well to other weight loss drugs.
The approval also positions Novo Nordisk competitively as Eli Lilly's experimental pill orforglipron succeeded in late-stage testing this year and may be approved within weeks thanks to a "national priority" voucher awarded by the FDA.
What This Means for You
If you're currently on Wegovy 2.4 mg but haven't achieved your weight loss goals, Wegovy HD could provide a new path forward without switching medication classes entirely. The key requirement is demonstrating tolerance to the current maximum dose for at least four weeks.
However, the higher rate of skin sensitivity side effects means you'll want to discuss this thoroughly with your healthcare provider. The good news is that most of these symptoms resolved on their own or with dose adjustments.
For those exploring GLP-1 options for the first time, you can compare costs across different medications and access methods. Remember that insurance coverage for the new higher dose may initially be limited, so cash-pay options through various channels may be worth considering.
If you're interested in finding providers who will offer Wegovy HD once it launches in April, use our find a clinic near you directory to locate healthcare providers experienced with GLP-1 medications in your area.
Sources
- FDA approves fourth product under National Priority Voucher Program, higher dose semaglutide - Official FDA press release announcing Wegovy HD approval
- Higher-Dose Semaglutide Approved Under New FDA Accelerated Review Process - AJMC coverage of accelerated approval timeline
- Wegovy HD (semaglutide 7.2 mg) approved in the US - Novo Nordisk official announcement with clinical trial details
- FDA Approves Higher-Dose Semaglutide Under Accelerated Review Program - Pharmacy Times analysis of clinical data and safety profile